Absence of an interaction between tigecycline and digoxin in healthy men

Pharmacotherapy

Volumn 27, Issue 6, 2007, Pages 835-844

  Zimmerman, James J ^a   Harper, Dawn M ^a   Matschke, Kyle ^a   Speth, John L ^a   Raible, Donald G ^a   Fruncillo, Richard J ^a  

^a PFIZER INC   (United States)

Author keywords

Antibiotics; Digitalis; Digoxin; Drug interactions; Glycylcyclines; Pharmacodynamics; Pharmacokinetics; Tigecycline

Indexed keywords

DIGOXIN; TIGECYCLINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DYSPEPSIA; ELECTROCARDIOGRAPHY; EVALUATION; HEADACHE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE REACTION; LOADING DRUG DOSE; MALE; NAUSEA; NORMAL HUMAN; QT INTERVAL; RADIOIMMUNOASSAY; SINGLE DRUG DOSE; STEADY STATE; TANDEM MASS SPECTROMETRY; URINARY EXCRETION; VOMITING;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CARDIOTONIC AGENTS; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; DIGOXIN; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; RADIOIMMUNOASSAY;

EID: 34249812684     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.6.835     Document Type: Article

References (43)

1. Bradford P, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials for complicated skin and skin structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005;41:S315-32.
2. Wyeth Pharmaceuticals Inc. Tygacil (tigecycline) package insert. Philadelphia, PA; 2005.
3. Betriu C, Culebras E, Rodriguez-Avial I, Gomez M, Sanchez BA, Picazo JJ. In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance. Antimicrob Agents Chemother 2004;48:323-5.
4. Betriu C, Rodriguez-Avial I, Sanchez BA, et al. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob Agents Chemother 2002;46:892-5.
5. Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn Microbiol Dis 2001;40:173-7.
6. Edelstein PH, Weiss WJ, Edelstein MA. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 2003;47:533-40.
7. Gales AC, Silva JB, Andrade SS, Sader HS, Jones RN. In vitro activity of the tigecycline, a new glycylycline, tested against 1326 clinical bacterial strains isolated from the Latin American region [abstract]. In: Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2003:207.
8. Edlund C, Nord CE. In-vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin Microbiol Infect 2000;6:159-63.
9. Nannini EC, Pai SR, Singh KV, Murray BE. Activity of tigecycline (GAR-936), a novel glycylcycline, against enterococci in the mouse peritonitis model. Antimicrob Agents Chemother 2003;47:529-32.
10. Patel R, Rouse MS, Piper KE, Steckelberg JM. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2000;38:177-9.
11. Murray J, Wilson S, Klein S, Yellin A, Loh E. The clinical response to tigecycline in the treatment of complicated intraabdominal infections in hospitalized patients: a phase 2 clinical trial [abstract]. In: Program and abstracts of the 43rd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2003:416.
12. Postier RG, Green SL, Klein SR, Ellis-Grosse EJ, Loh E, for the Tigecycline 200 Study Investigators. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin structure infections in hospitalized patients. Clin Ther 2004;26:704-14.
13. Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005;9:251-61.
14. Oliva ME, Rekha A, Yellin A, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [online exclusive article]. BMC Infect Dis 2005;5:88. Available from http://www.biomedcentral.com/1471-2334/5/88.
15. Fomin P, Beuran M, Gradauskas A, et al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg 2005;3:35-47.
16. Breedt J, Teras J, Gardovskis J, et al. The safety and efficacy of tigecycline in the treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin/aztreonam. Antimicrob Agents Chemother 2005;49:4658-66.
17. Lefort A, Lafaurie M, Massias L, et al. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2003;47:216-22.
18. Harms JM, Bartels H, Schlunzen F, Yonath A. Antibiotics acting on the translational machinery. J Cell Sci 2003;116(pt 8):1391-3.
19. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001;65:232-60.
20. Chopra I. New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors. Drug Resist Updat 2002;5:119-25.
21. + antiporter. Antimicrob Agents Chemother 1995;39:247-9.
22. Rasmussen BA, Gluzman Y, Tally FP. Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob Agents Chemother 1994;38:1658-60.
23. Muralidharan G, Fruncillo RJ, Micalizzi M, Raible DG, Troy SM. Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. Antimicrob Agents Chemother 2005;49:1656-9.
24. Sesoko S, Umemura K, Nakashima M. Pharmacokinetics (PK), safety, and tolerability of tigecycline (GAR-936) in healthy Japanese males [abstract]. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2002:abstract A-1403.
25. Muralidharan G, Micalizzi M, Speth J, Raible DG, Troy SM. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005;49:220-9.
26. Sun HK, Ong CT, Umer A, Harper D, Troy S, Nightingale CH. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 2005;49:1629-32.
27. Om A, Hess ML. Inotropic therapy of the failing myocardium. Clin Cardiol 1993;16:5-14.
28. Tisdale JE, Gheorghiade M. Acute hemodynamic effects of digoxin alone or in combination with other vasoactive agents in patients with congestive heart failure. Am J Cardiol 1992;69:G34-47.
29. Koren G, Woodland C, Ito S. Toxic digoxin-drug interactions: the major role of renal P-glycoprotein. Vet Hum Toxicol 1998;40:45-6.
30. GlaxoSmithKline. Lanoxin (digoxin) package insert. Research Triangle Park, NC; 2001.
31. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999;104:147-53.
32. Tanigawara Y, Okamura N, Hirai M, et al. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 1992;263:840-5.
33. Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, Fromm MF. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther 2003;73: 223-31.
34. Schentag JJ, Bang AJ, Kozinski-Tobar J. Digoxin. In: Burton ME, Schentag JJ, Shaw LM, Evans WE, eds. Applied pharmacokinetics and pharmacodynamics: principles of therapeutic drug monitoring. Philadelphia: Lippincott Williams and Wilkins, 2006:410-39.
35. Lindenbaum J, Rund DG, Butler VP Jr, Tse-Engl D, Saha JR. Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med 1981;305:789-94.
36. Saha JR, Butler VP Jr, Neu HC, Lindenbaum J. Digoxin-inactivating bacteria: identification in human gut flora. Science 1983;220:325-7.
37. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker, Inc., 1982.
38. Colburn WA. Estimating the accumulation of drugs. J Pharm Sci 1983;72:833-4.
39. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15:657-80.
40. 14C] tigecycline in human volunteers following intravenous infusion. Presented at the meeting of the American Association of Pharmaceutical Scientists, Baltimore, MD, November 7-11, 2004.
41. Lindenbaum J, Tse-Engl D, Butler VP Jr, Rund DG. Urinary excretion of reduced metabolites of digoxin. Am J Med 1981;71:67-74.
42. Butler VPJ, Tse-Engl D, Lindenbaum J, Kalman S, Preibisz J, Levitan S. Radioimmunoassay for diyhdrodigoxin: development and application [abstract]. Circulation 1980;62(suppl3):III-293.
43. Meagher AK, Ambrose P, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005;41:S333-40.